Navigation Links
Watson Pharmaceuticals Reports Second Quarter 2008 Results
Date:8/6/2008

p>

Three Months Ended Six Months Ended

June 30, June 30,

2008 2007 2008 2007

GAAP net income $60.3 $36.4 $110.9 $68.0

Plus:

Interest expense 6.9 11.5 13.7 25.4

Interest income (1.7) (1.8) (4.0) (4.7)

Provision for income taxes 35.6 21.0 66.7 41.0

Depreciation (2008 includes

accelerated depreciation) 22.4 19.5 44.2 37.5

Amortization 20.2 44.1 40.4 88.1

EBITDA 143.7 130.7 271.9 255.3

Adjusted for:

Share-based compensation 4.9 3.5 9.3 6.9

Acquisition and licensing charges 0.5 2.2 5.5 9.6

Legal settlement (15.0) (0.8) (15.0) 0.2

Loss on early extinguishment of

debt - 1.7 1.1 4.4

Global supply chain initiative 3.4 - 15.4 -

Gain on sale of assets - (0.7) (1.4) (2.5)

Adjusted EBITDA $137.5 $136.6 $286.8 $273.9

The following table presents a reconciliation of forecasted net income for the 12 months ending December 31, 2008 to adjusted net income and adjusted earnings per diluted share:

Table 6

Watson Pharmaceuticals, Inc.

Reconciliation Table - Forecasted Adjusted Earnings per Diluted Share

(Unaudited; in millions except per share amounts)

Forecast for Twelve M
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. Watson to Present at the Bear Stearns 20th Annual Healthcare Conference
2. Watson Receives FDA Approval for Generic Accuneb(R)
3. Warner Chilcott and Watson Pharmaceuticals Announce Launch of Tilia(TM) Fe
4. Watson to Present at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
5. Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results; Provides 2008 Outlook
6. Barr Subsidiary Sues Watson for SEASONIQUE(R) Patent Infringement
7. Watson Files FDA Application for Generic LYBREL(R)
8. FDA Approves MIXJECT(TM), a Convenient, Easy-to-Use Drug Delivery System For Watson Pharmaceuticals TRELSTAR(R) DEPOT and TRELSTAR(R) LA
9. Cephalon Files Patent Infringement Lawsuit Against Watson Pharmaceuticals
10. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
11. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... 2014 New spin-out from ... Cambridge Innovation Capital and Johnson & Johnson Development ... company focused on harnessing the potential of circulating ... and treatment, today announced it has raised £4m ... and including Cambridge Innovation Capital and Johnson & ...
(Date:9/22/2014)... (PRWEB) September 22, 2014 Pearl's Premium ... breakthrough in drought tolerant grass seed this week with ... seed. The announcement coincides with the fact that it ... Spring as many believe. , As of the ... and favorable reviews by industry experts and the media ...
(Date:9/22/2014)... , September 22, 2014 ... the addition of the "Global Biotechnology Reagents ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) Biotechnology reagents ... to a system to detect and examine another ... generally used in laboratories to prepare, collect, and ...
(Date:9/22/2014)... it is to stop bleeding, are very simple. They ... the physical environment around them, researchers at Emory and ... with greater stiffness by increasing their stickiness, the degree ... components of the clotting system, the researchers found. , ... in that they are able to sense the physical ...
Breaking Biology Technology:Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 2Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 3Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 4Pearl's Premium Ultra Low Maintenance Lawn Seed Announces A Major Breakthrough In Drought Tolerant Grass Seed 2Global Biotechnology Reagents Market 2014-2018: Key Vendors are Agilent, BD Biosciences, Bio-Rad, F. Hoffmann-La Roche, Sigma-Aldrich and Thermo Fisher 2Global Biotechnology Reagents Market 2014-2018: Key Vendors are Agilent, BD Biosciences, Bio-Rad, F. Hoffmann-La Roche, Sigma-Aldrich and Thermo Fisher 3Platelets modulate clotting behavior by 'feeling' their surroundings 2
... Texas, Jan. 5, 2012  Healthpoint Biotherapeutics today announced that ... Robert Bancroft, Executive Vice President, Strategic and Commercial Development, ... products and its R&D pipeline at the upcoming J.P. ... January 9th, at 9:30 am (PST) at the Westin ...
... Biosystems, Inc. (OTCBB:WGBS), an emerging genomic analysis company, today ... presentation at the 5 th Annual OneMedForum San ... Francisco, Calif., January 9-12, 2012. The company ... beginning at 10:00 a.m. Pacific Time.  The presentation will ...
... 5, 2012  ZyGEM Corp. Ltd., a developer and ... DNA and other nucleic acids, and the US ... today announced the signing of a Cooperative Research ... simplified sample processing solutions for biothreat agents.  The ...
Cached Biology Technology:WaferGen to Present Corporate Overview at 5th Annual OneMedForum San Francisco 2012 2ZyGEM and USAMRIID Sign CRADA for Development of Simplified Sample Processing Solutions for Biothreat Agents 2ZyGEM and USAMRIID Sign CRADA for Development of Simplified Sample Processing Solutions for Biothreat Agents 3
(Date:9/23/2014)... times more carbon than the atmosphere and small ... big effect on atmospheric greenhouse gas concentrations. A ... Change concludes that climate warming does not ... carbon storage, despite increases in ecosystem productivity. ... Research Ecologist Dr. Christian Giardina, with the agency,s ...
(Date:9/23/2014)... temperature on insects to predict how climate change will ... shows for the first time that insects, fear of ... fast they grow. , "In other words, it,s less ... that shape the growth, survival and distribution of insects." ... an Arctic postdoctoral researcher at Dartmouth. , The ...
(Date:9/23/2014)... Eureka Therapeutics, Inc. announced today that the Company has ... new funding will be used to expand the Company,s ... clinical development. New investor Yuan Capital led the round, ... including Acorn Campus Ventures, Suma Venture and Harbinger Venture ... and development of fully-human antibodies engineered to mimic the ...
Breaking Biology News(10 mins):Study helps assess impact of temperature on belowground soil decomposition 2Insects' fear limits boost from climate change, Dartmouth study shows 2
... SAN DIEGO, Calif. (March 10, 2009)Attempts to treat ... patients with below-the-knee angioplasty are still thwarted by ... site of angioplasty or stenting), the need for ... disease, leading to tissue death (gangrene) and amputation. ...
... SAN DIEGO, Calif. (March 10, 2009)The use of common ... (ABI)along with traditional risk scoring systemssuch as the Framingham ... in thousands of individuals who are not originally thought ... say researchers at the Society of Interventional Radiology,s 34th ...
... March 9 Explorations Group Inc. (OTC Bulletin ... letter of intent to acquire Daniel R. Smith & Associates, ... total of $4.2 million to be paid in a combination ... Intent, EXGI President David Coriaty stated "the acquisition of DRSA ...
Cached Biology News:Promising 3-year data: Saving limbs with drug-eluting stents 2Promising 3-year data: Saving limbs with drug-eluting stents 3Simple test helps predict heart attack risk 2Simple test helps predict heart attack risk 3Explorations Group Announces Letter of Intent to Acquire Specialty Lighting Company 2
IHC detection kit for PCNA in cells and tissues...
Request Info...
... Immunogen: Synthetic peptide derived from ... WNT1 protein. Specificity: Reacts with ... Reactivity: Human Mouse (positive controls: ... cell lysates and mouse Mouse-1 cell ...
... Nick Translation System is ideal for both ... Nick Translation System: Provides five pre-mixed ... incorporation Yields >10 8 cpm/g ... DNA to monitor the performance of the ...
Biology Products: